TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With

Asma Dilawari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.